Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1D1 | P20393 | 4/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | MMP9 | P14780 | 6/20 | 0.34 |
| ▸ | MMP3 | P08254 | 5/20 | 0.34 |
| ▸ | MMP8 | P22894 | 4/20 | 0.34 |
| ▸ | MMP1 | P03956 | 3/20 | 0.34 |
| ▸ | ADAM17 | P78536 | 3/20 | 0.34 |
| ▸ | ADAM9 | Q13443 | 3/20 | 0.34 |
| ▸ | NAMPT | P43490 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4925547 | 0.83 | NR1D1 (0.40) | NR1D1MMP9MMP3MMP1ADAM17 | |
| SCHEMBL4648640 | 0.81 | TDP1 (0.40) | POLBMMP9MMP3MMP8MMP1 | |
| SCHEMBL28057905 | 0.76 | NR1D1 (0.41) | NR1D1POLBMMP9MMP3MMP8 | |
| SCHEMBL12191655 | 0.74 | ACE (0.51) | POLBMMP3MMP8 | |
| SCHEMBL6370245 | 0.72 | NR1D1 (0.58) | NR1D1POLBMMP9MMP3MMP8 | |
| SCHEMBL16879293 | 0.68 | NR1D1 (0.59) | NR1D1POLBMMP9MMP3MMP8 | |
| SCHEMBL6369530 | 0.68 | NR1D1 (0.45) | NR1D1MMP9MMP3MMP1ADAM17 | |
| SCHEMBL12125014 | 0.68 | NR1D1 (0.45) | NR1D1MMP9MMP3MMP1ADAM17 | |
| SCHEMBL7536950 | 0.67 | ACE (0.49) | POLBMMP9MMP3MMP8MMP1 | |
| SCHEMBL7536956 | 0.67 | ACE (0.49) | POLBMMP9MMP3MMP8MMP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080255188-A1 | Muscarinic Receptor Antagonists | RANBAXY LABORATORIES LIMITED (IN) | 2008-10-16 | — | — | US | claimed |
| EP-1904495-A2 | MUSCARINIC RECEPTOR ANTAGONISTS | Ranbaxy Laboratories Limited (IN) | 2008-04-02 | — | — | EP | claimed |
| WO-2007007281-A2 | MUSCARINIC RECEPTOR ANTAGONISTS | RANBAXY LABORATORIES LIMITED (IN) | 2007-01-18 | — | — | WO | claimed |
| US-20080255188-A1 | Muscarinic Receptor Antagonists | RANBAXY LABORATORIES LIMITED (IN) | 2008-10-16 | — | — | US | disclosed |
| EP-1904495-A2 | MUSCARINIC RECEPTOR ANTAGONISTS | Ranbaxy Laboratories Limited (IN) | 2008-04-02 | — | — | EP | disclosed |
| WO-2007007281-A2 | MUSCARINIC RECEPTOR ANTAGONISTS | RANBAXY LABORATORIES LIMITED (IN) | 2007-01-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080255188-A1 | Muscarinic Receptor Antagonists | CHRM3, CHRM5, CHRM2 | NR1D1 774/4885POLB 3669/4885MMP9 3432/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.